The pharmaceutical industry may have arrived at its own version
of ‘publish or perish’: ‘Develop or disappear’. In 2008, as reported in Chemistry World, Glaxo Smith Kline (GSK) instituted a policy requiring its research teams to pitch and defend their research programs
to executives and outside analysts, a la
the U.S. television show Shark Tank. Three
years later, as reported on 21 August in The Sunday Times (and freely accessible on the Ottawa Citizen) those teams are up for a progress review — and not everyone will make the cut.